The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
about
Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse modelsScreening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interferenceRasGRPs are targets of the anti-cancer agent ingenol-3-angelateTattoo removal with ingenol mebutate.Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.Ablative fractional laser alters biodistribution of ingenol mebutate in the skin.Development of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation.Ingenol mebutate treatment in keloidsSome phorbol esters might partially resemble bryostatin 1 in their actions on LNCaP prostate cancer cells and U937 leukemia cellsIL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice.New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 miceBeyond 3D culture models of cancer.In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.Regioselective enzymatic acylation of complex natural products: expanding molecular diversity.Specifying protein kinase C functions in melanoma.Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.Natural product and natural product derived drugs in clinical trials.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers.Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.Ingenol-3-Angelate Suppresses Growth of Melanoma Cells and Skin Tumor Development by Downregulation of NF-κB-Cox2 Signaling.Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.Gene discovery of modular diterpene metabolism in nonmodel systems.Mechanism of inhibition of Shiga-toxigenic Escherichia coli SubAB cytotoxicity by steroids and diacylglycerol analogues.Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practiceIngenol mebutate induces a tumor cell-directed inflammatory response and antimicrobial peptides thereby promoting rapid tumor destruction and wound healing
P2860
Q21089659-10F37383-590F-412C-A0F1-89BAF6E10927Q28486133-1DB435EC-60FC-468E-9AC0-ABEB9323DDB7Q28535474-29D7B232-CA01-4066-B890-4A9DADE96ECFQ33739024-C70F414D-0EEF-4A8C-B286-0E80FFB60E1DQ35252396-43C9550E-F3F1-433C-8454-3F92CAC84229Q35592491-4087066D-FBE4-4017-996B-1995D9F3C11AQ35635404-709F9D14-0201-4A3A-9A08-D2AB6F7CB9D8Q35782496-111063D8-8CF0-47F6-A4EA-86C46E58DA06Q35856396-8538ECD8-B870-4199-A44F-8443B569848FQ35996041-837854FA-436B-407B-A848-D7F9DEC49B7FQ36128569-2A5B0B00-5AA6-45AE-A8D6-8EE0305D7F17Q36135774-34831B2A-4F43-4546-BD30-E83E91F433B6Q36196699-C4178535-F186-4C44-AC99-838FC8E47D60Q36503300-E86327E7-F60A-4D23-9A11-03C64BD29C59Q37338293-189E440F-1F8C-43F2-9E14-F344489E20D2Q37493633-376EBD19-9842-448D-BEAB-0EE1B02A9CC4Q37892390-30A129C4-0EF5-49F5-B83B-88F67D5E0D0AQ38009398-2A02630B-6EC4-4A93-8EDF-DC526C73441DQ38066531-C4EEB19D-027D-4D34-806A-B79BA50C809EQ38106805-4271942A-E103-443A-94BB-2FC18EE0B1D5Q38247457-F5C8F8AC-8CCF-463D-B568-FEF3BEB44FE2Q38546598-85E23082-39B4-4BBF-A9A7-6B91E0BD9E27Q38622474-C0AB4B63-577A-413E-9BAA-6712A8160FCBQ42484803-BFB8380C-3A6B-444D-B463-48845C8CB026Q47096038-9B265C21-5EAA-45C8-BE90-5DDF11789339Q47549240-7EEA5683-F96B-4707-B0FD-7541E0E1A313Q48333084-F16F5C5A-8099-4261-BD45-DF5B3D9BA506Q51046887-9EC8FE06-518E-495F-8295-CED0CC1DC654Q52659226-9C742E12-A661-4F8A-A6D6-38BBE43BC014Q57484131-100B6A7F-C1EB-4E39-871C-7A21609690D0Q59126626-06847314-63C8-439B-A3A9-A8DDCA8495AC
P2860
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The skin cancer chemotherapeut ...... and targets tumor vasculature.
@ast
The skin cancer chemotherapeut ...... and targets tumor vasculature.
@en
type
label
The skin cancer chemotherapeut ...... and targets tumor vasculature.
@ast
The skin cancer chemotherapeut ...... and targets tumor vasculature.
@en
prefLabel
The skin cancer chemotherapeut ...... and targets tumor vasculature.
@ast
The skin cancer chemotherapeut ...... and targets tumor vasculature.
@en
P2093
P2860
P1433
P1476
The skin cancer chemotherapeut ...... and targets tumor vasculature.
@en
P2093
Andrew Lee
David J Maloney
Stuart H Yuspa
Suneet Shukla
Suresh V Ambudkar
Susan H Garfield
P2860
P304
P356
10.1158/0008-5472.CAN-09-4303
P407
P577
2010-05-11T00:00:00Z